Sintx Technologies, Inc. (SINT)
NASDAQ: SINT · Real-Time Price · USD
3.210
-0.130 (-3.89%)
At close: Nov 21, 2025, 4:00 PM EST
3.260
+0.050 (1.56%)
After-hours: Nov 21, 2025, 5:03 PM EST
Sintx Technologies Revenue
Sintx Technologies had revenue of $208.00K in the quarter ending September 30, 2025, a decrease of -73.97%. This brings the company's revenue in the last twelve months to $1.27M, down -60.89% year-over-year. In the year 2024, Sintx Technologies had annual revenue of $2.89M with 9.90% growth.
Revenue (ttm)
$1.27M
Revenue Growth
-60.89%
P/S Ratio
5.42
Revenue / Employee
$63,500
Employees
20
Market Cap
12.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.89M | 260.00K | 9.90% |
| Dec 31, 2023 | 2.63M | 1.07M | 68.29% |
| Dec 31, 2022 | 1.56M | 955.00K | 157.59% |
| Dec 31, 2021 | 606.00K | 12.00K | 2.02% |
| Dec 31, 2020 | 594.00K | -95.00K | -13.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SINT News
- 19 days ago - SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System - GlobeNewsWire
- 4 weeks ago - SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System - GlobeNewsWire
- 5 weeks ago - SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics - GlobeNewsWire
- 2 months ago - SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent - GlobeNewsWire
- 3 months ago - SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition - GlobeNewsWire
- 3 months ago - SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates - GlobeNewsWire
- 5 months ago - SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market - GlobeNewsWire